4.5 Review

Luminogenic cytochrome P450 assays

Journal

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
Volume 2, Issue 4, Pages 629-645

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1517/17425255.2.4.629

Keywords

CYP; CYP induction; CYP inhibition; cytochrome P450; drug-drug interaction; drug metabolism; fluorescent P450 assay; hepatocyte; high-throughput screening; liver microsomes; luminescent P450 assay; P450-Glo (TM); recombinant CYP enzymes

Ask authors/readers for more resources

Luminogenic cytochrome P450 (CYP) assays couple CYP enzyme activity to firefly luciferase luminescence in a technology called P450-Glo (TM) (Promega). Luminogenic substrates are used in assays of human CYP1A1, -1A2, -1B1, -2C8, -2C9, -2C19, -2D6, -2J2, -3A4, -3A7; -4A11, -4F3B, -4F12 and -19. The assays detect dose-dependent CYP inhibition by test compounds against recombinant CYP enzymes or liver microsomes. Induction or inhibition of CYP activities in cultured hepatocytes is measured in a nonlytic approach that leaves cells intact for additional analysis: Luminogenic CYP assays offer advantages of speed and safety over HPLC and radiochemical-based methods. Compared with fluorogenic methods the approach offers advantages of improved sensitivity and decreased interference between optical properties of test compound and CYP substrate. These homogenous assays are sensitive and robust tools for high-throughput CYP screening in early drug discovery.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available